Rituximab (Anti-Human CD20 type I, Chimeric Antibody) (Synonyms: IDEC-C2B8) |
Catalog No.GC34209 |
Rituximab (Anti-Human CD20 type I, Chimeric Antibody) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 174722-31-7
Sample solution is provided at 25 µL, 10mM.
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma [1].
Intravenously administered rituximab was granted regulatory approval in 1997 by the US Food and Drug Administration and in 1998 by the European Medicines Agency for use in relapsed/refractory indolent non-Hodgkin lymphomas. Approvals for use in chronic lymphocytic leukemia followed in 2009 and 2010, respectively [1].
Rituximab binds with high affinity and specificity to the CD20 antigen, which is expressed on the vast majority of malignant B cells. The apparent affinity constant of rituximab for human CD20, as determined by Scatchard analysis using a human lymphoblastoid cell line, is approximately 5.2 nmol/L [2]. Rituximab provides significant, clinically meaningful benefits to patients with active rheumatoid arthritis also. In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48 [3].
References:
[1]. Salles G, Barrett M, FoÀ R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232-2273.
[2]. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-45.
[3]. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581
Average Rating: 5
(Based on Reviews and 33 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *